Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis
Estimating the risk of pre-existing comorbidities on coronavirus disease 2019 (COVID-19) mortality may promote the importance of targeting populations at risk to improve survival. This systematic review and meta-analysis aimed to estimate the association of pre-existing comorbidities with COVID-19 m...
Gespeichert in:
| Veröffentlicht in: | PloS one 2020-08, Vol.15 (8), p.e0238215-e0238215 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0238215 |
|---|---|
| container_issue | 8 |
| container_start_page | e0238215 |
| container_title | PloS one |
| container_volume | 15 |
| creator | Ssentongo, Paddy Ssentongo, Anna E Heilbrunn, Emily S Ba, Djibril M Chinchilli, Vernon M |
| description | Estimating the risk of pre-existing comorbidities on coronavirus disease 2019 (COVID-19) mortality may promote the importance of targeting populations at risk to improve survival. This systematic review and meta-analysis aimed to estimate the association of pre-existing comorbidities with COVID-19 mortality.
We searched MEDLINE, SCOPUS, OVID, and Cochrane Library databases, and medrxiv.org from December 1st, 2019, to July 9th, 2020. The outcome of interest was the risk of COVID-19 mortality in patients with and without pre-existing comorbidities. We analyzed 11 comorbidities: cardiovascular diseases, hypertension, diabetes, congestive heart failure, cerebrovascular disease, chronic kidney disease, chronic liver disease, cancer, chronic obstructive pulmonary disease, asthma, and HIV/AIDS. Two reviewers independently extracted data and assessed the risk of bias. All analyses were performed using random-effects models and heterogeneity was quantified.
Eleven pre-existing comorbidities from 25 studies were included in the meta-analysis (n = 65, 484 patients with COVID-19; mean age; 61 years; 57% male). Overall, the between-study heterogeneity was medium, and studies had low publication bias and high quality. Cardiovascular disease (risk ratio (RR) 2.25, 95% CI = 1.60-3.17, number of studies (n) = 14), hypertension (1.82 [1.43 to 2.32], n = 13), diabetes (1.48 [1.02 to 2.15], n = 16), congestive heart failure (2.03 [1.28 to 3.21], n = 3), chronic kidney disease (3.25 [1.13 to 9.28)], n = 9) and cancer (1.47 [1.01 to 2.14), n = 10) were associated with a significantly greater risk of mortality from COVID-19.
Patients with COVID-19 with cardiovascular disease, hypertension, diabetes, congestive heart failure, chronic kidney disease and cancer have a greater risk of mortality compared to patients with COVID-19 without these comorbidities. Tailored infection prevention and treatment strategies targeting this high-risk population might improve survival. |
| doi_str_mv | 10.1371/journal.pone.0238215 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2437389491</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A633597924</galeid><doaj_id>oai_doaj_org_article_e7bb499c205145098753e03c77e55c4a</doaj_id><sourcerecordid>A633597924</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-578c26bc1f176ee1679b663dce0d623b99b2149d4f92fcee846d1acd2abf26603</originalsourceid><addsrcrecordid>eNqNk9tqGzEQhpfS0qRp36C0gkJpL9bVabWrXhRMejIEDD3kVmi1s7bM7sqRtEn8Dn3oyrET4pKLogsJzTf_aEYzWfaS4AlhJfmwcqMfdDdZuwEmmLKKkuJRdkwko7mgmD2-dz7KnoWwwrhglRBPsyNGK15IKo6zP9MQnLE6Wjcg1yKjfWPdpQ5m7LRHjQ2gAyA9NIhg5OISPFp7yOHahmiHBTKud762jY0WArqycYlO5-ezzzmRKFmi7mzcfERTFDYhQp8CGeTh0sLVjWgPUec65bEJNjzPnrS6C_Biv59kv79--XX6PT-bf5udTs9yIySNeVFWhorakJaUAoCIUtZCsMYAbgRltZQ1JVw2vJW0NQAVFw3RpqG6bqkQmJ1kr3e6684FtS9kUJSzklWSS5KI2Y5onF6ptbe99hvltFU3F84vlPYplQ4UlHXNpTQUF4QXWFZlwQAzU5ZQFIbrpPVpH22se0ivHKLX3YHooWWwS7Vwl6rkXPJSJIF3ewHvLkYIUfU2GOg6PYAbd--uCioxS-ibf9CHs9tTC50SsEPrUlyzFVVTwVghS5nok2zyAJVWA701qetam-4PHN4fOCQmwnVc6DEENfv54__Z-fkh-_YeuwTdxWVw3bjt2XAI8h1ovAvBQ3tXZILVdmhuq6G2Q6P2Q5PcXt3_oDun2ylhfwFkpBLZ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2437389491</pqid></control><display><type>article</type><title>Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Ssentongo, Paddy ; Ssentongo, Anna E ; Heilbrunn, Emily S ; Ba, Djibril M ; Chinchilli, Vernon M</creator><contributor>Hirst, Jennifer A.</contributor><creatorcontrib>Ssentongo, Paddy ; Ssentongo, Anna E ; Heilbrunn, Emily S ; Ba, Djibril M ; Chinchilli, Vernon M ; Hirst, Jennifer A.</creatorcontrib><description>Estimating the risk of pre-existing comorbidities on coronavirus disease 2019 (COVID-19) mortality may promote the importance of targeting populations at risk to improve survival. This systematic review and meta-analysis aimed to estimate the association of pre-existing comorbidities with COVID-19 mortality.
We searched MEDLINE, SCOPUS, OVID, and Cochrane Library databases, and medrxiv.org from December 1st, 2019, to July 9th, 2020. The outcome of interest was the risk of COVID-19 mortality in patients with and without pre-existing comorbidities. We analyzed 11 comorbidities: cardiovascular diseases, hypertension, diabetes, congestive heart failure, cerebrovascular disease, chronic kidney disease, chronic liver disease, cancer, chronic obstructive pulmonary disease, asthma, and HIV/AIDS. Two reviewers independently extracted data and assessed the risk of bias. All analyses were performed using random-effects models and heterogeneity was quantified.
Eleven pre-existing comorbidities from 25 studies were included in the meta-analysis (n = 65, 484 patients with COVID-19; mean age; 61 years; 57% male). Overall, the between-study heterogeneity was medium, and studies had low publication bias and high quality. Cardiovascular disease (risk ratio (RR) 2.25, 95% CI = 1.60-3.17, number of studies (n) = 14), hypertension (1.82 [1.43 to 2.32], n = 13), diabetes (1.48 [1.02 to 2.15], n = 16), congestive heart failure (2.03 [1.28 to 3.21], n = 3), chronic kidney disease (3.25 [1.13 to 9.28)], n = 9) and cancer (1.47 [1.01 to 2.14), n = 10) were associated with a significantly greater risk of mortality from COVID-19.
Patients with COVID-19 with cardiovascular disease, hypertension, diabetes, congestive heart failure, chronic kidney disease and cancer have a greater risk of mortality compared to patients with COVID-19 without these comorbidities. Tailored infection prevention and treatment strategies targeting this high-risk population might improve survival.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0238215</identifier><identifier>PMID: 32845926</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Acquired immune deficiency syndrome ; Aged ; AIDS ; Asthma ; Bias ; Biology and Life Sciences ; Cancer ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - mortality ; Cerebrovascular diseases ; Chronic diseases ; Chronic obstructive pulmonary disease ; Comorbidity ; Complications and side effects ; Congestive heart failure ; Coronary artery disease ; Coronavirus Infections - mortality ; Coronaviruses ; COVID-19 ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus - mortality ; Failure analysis ; Female ; Health risks ; Heterogeneity ; HIV ; Human immunodeficiency virus ; Humans ; Hypertension ; Kidney diseases ; Kidneys ; Liver cancer ; Liver diseases ; Lung cancer ; Lung diseases ; Male ; Medicine and Health Sciences ; Meta-analysis ; Middle Aged ; Mortality ; Mortality risk ; Neoplasms - mortality ; Obstructive lung disease ; Pandemics ; Patient outcomes ; People and Places ; Pneumonia, Viral - mortality ; Prognosis ; Renal failure ; Renal Insufficiency, Chronic - mortality ; Risk assessment ; Survival ; Viral diseases</subject><ispartof>PloS one, 2020-08, Vol.15 (8), p.e0238215-e0238215</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Ssentongo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Ssentongo et al 2020 Ssentongo et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-578c26bc1f176ee1679b663dce0d623b99b2149d4f92fcee846d1acd2abf26603</citedby><cites>FETCH-LOGICAL-c692t-578c26bc1f176ee1679b663dce0d623b99b2149d4f92fcee846d1acd2abf26603</cites><orcidid>0000-0003-1565-5731 ; 0000-0001-9104-1323 ; 0000-0002-9868-5495</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449476/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449476/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,2915,23847,27905,27906,53772,53774,79349,79350</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32845926$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Hirst, Jennifer A.</contributor><creatorcontrib>Ssentongo, Paddy</creatorcontrib><creatorcontrib>Ssentongo, Anna E</creatorcontrib><creatorcontrib>Heilbrunn, Emily S</creatorcontrib><creatorcontrib>Ba, Djibril M</creatorcontrib><creatorcontrib>Chinchilli, Vernon M</creatorcontrib><title>Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Estimating the risk of pre-existing comorbidities on coronavirus disease 2019 (COVID-19) mortality may promote the importance of targeting populations at risk to improve survival. This systematic review and meta-analysis aimed to estimate the association of pre-existing comorbidities with COVID-19 mortality.
We searched MEDLINE, SCOPUS, OVID, and Cochrane Library databases, and medrxiv.org from December 1st, 2019, to July 9th, 2020. The outcome of interest was the risk of COVID-19 mortality in patients with and without pre-existing comorbidities. We analyzed 11 comorbidities: cardiovascular diseases, hypertension, diabetes, congestive heart failure, cerebrovascular disease, chronic kidney disease, chronic liver disease, cancer, chronic obstructive pulmonary disease, asthma, and HIV/AIDS. Two reviewers independently extracted data and assessed the risk of bias. All analyses were performed using random-effects models and heterogeneity was quantified.
Eleven pre-existing comorbidities from 25 studies were included in the meta-analysis (n = 65, 484 patients with COVID-19; mean age; 61 years; 57% male). Overall, the between-study heterogeneity was medium, and studies had low publication bias and high quality. Cardiovascular disease (risk ratio (RR) 2.25, 95% CI = 1.60-3.17, number of studies (n) = 14), hypertension (1.82 [1.43 to 2.32], n = 13), diabetes (1.48 [1.02 to 2.15], n = 16), congestive heart failure (2.03 [1.28 to 3.21], n = 3), chronic kidney disease (3.25 [1.13 to 9.28)], n = 9) and cancer (1.47 [1.01 to 2.14), n = 10) were associated with a significantly greater risk of mortality from COVID-19.
Patients with COVID-19 with cardiovascular disease, hypertension, diabetes, congestive heart failure, chronic kidney disease and cancer have a greater risk of mortality compared to patients with COVID-19 without these comorbidities. Tailored infection prevention and treatment strategies targeting this high-risk population might improve survival.</description><subject>Acquired immune deficiency syndrome</subject><subject>Aged</subject><subject>AIDS</subject><subject>Asthma</subject><subject>Bias</subject><subject>Biology and Life Sciences</subject><subject>Cancer</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - mortality</subject><subject>Cerebrovascular diseases</subject><subject>Chronic diseases</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Comorbidity</subject><subject>Complications and side effects</subject><subject>Congestive heart failure</subject><subject>Coronary artery disease</subject><subject>Coronavirus Infections - mortality</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus - mortality</subject><subject>Failure analysis</subject><subject>Female</subject><subject>Health risks</subject><subject>Heterogeneity</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Kidney diseases</subject><subject>Kidneys</subject><subject>Liver cancer</subject><subject>Liver diseases</subject><subject>Lung cancer</subject><subject>Lung diseases</subject><subject>Male</subject><subject>Medicine and Health Sciences</subject><subject>Meta-analysis</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Mortality risk</subject><subject>Neoplasms - mortality</subject><subject>Obstructive lung disease</subject><subject>Pandemics</subject><subject>Patient outcomes</subject><subject>People and Places</subject><subject>Pneumonia, Viral - mortality</subject><subject>Prognosis</subject><subject>Renal failure</subject><subject>Renal Insufficiency, Chronic - mortality</subject><subject>Risk assessment</subject><subject>Survival</subject><subject>Viral diseases</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9tqGzEQhpfS0qRp36C0gkJpL9bVabWrXhRMejIEDD3kVmi1s7bM7sqRtEn8Dn3oyrET4pKLogsJzTf_aEYzWfaS4AlhJfmwcqMfdDdZuwEmmLKKkuJRdkwko7mgmD2-dz7KnoWwwrhglRBPsyNGK15IKo6zP9MQnLE6Wjcg1yKjfWPdpQ5m7LRHjQ2gAyA9NIhg5OISPFp7yOHahmiHBTKud762jY0WArqycYlO5-ezzzmRKFmi7mzcfERTFDYhQp8CGeTh0sLVjWgPUec65bEJNjzPnrS6C_Biv59kv79--XX6PT-bf5udTs9yIySNeVFWhorakJaUAoCIUtZCsMYAbgRltZQ1JVw2vJW0NQAVFw3RpqG6bqkQmJ1kr3e6684FtS9kUJSzklWSS5KI2Y5onF6ptbe99hvltFU3F84vlPYplQ4UlHXNpTQUF4QXWFZlwQAzU5ZQFIbrpPVpH22se0ivHKLX3YHooWWwS7Vwl6rkXPJSJIF3ewHvLkYIUfU2GOg6PYAbd--uCioxS-ibf9CHs9tTC50SsEPrUlyzFVVTwVghS5nok2zyAJVWA701qetam-4PHN4fOCQmwnVc6DEENfv54__Z-fkh-_YeuwTdxWVw3bjt2XAI8h1ovAvBQ3tXZILVdmhuq6G2Q6P2Q5PcXt3_oDun2ylhfwFkpBLZ</recordid><startdate>20200826</startdate><enddate>20200826</enddate><creator>Ssentongo, Paddy</creator><creator>Ssentongo, Anna E</creator><creator>Heilbrunn, Emily S</creator><creator>Ba, Djibril M</creator><creator>Chinchilli, Vernon M</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1565-5731</orcidid><orcidid>https://orcid.org/0000-0001-9104-1323</orcidid><orcidid>https://orcid.org/0000-0002-9868-5495</orcidid></search><sort><creationdate>20200826</creationdate><title>Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis</title><author>Ssentongo, Paddy ; Ssentongo, Anna E ; Heilbrunn, Emily S ; Ba, Djibril M ; Chinchilli, Vernon M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-578c26bc1f176ee1679b663dce0d623b99b2149d4f92fcee846d1acd2abf26603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Aged</topic><topic>AIDS</topic><topic>Asthma</topic><topic>Bias</topic><topic>Biology and Life Sciences</topic><topic>Cancer</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - mortality</topic><topic>Cerebrovascular diseases</topic><topic>Chronic diseases</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Comorbidity</topic><topic>Complications and side effects</topic><topic>Congestive heart failure</topic><topic>Coronary artery disease</topic><topic>Coronavirus Infections - mortality</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus - mortality</topic><topic>Failure analysis</topic><topic>Female</topic><topic>Health risks</topic><topic>Heterogeneity</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Kidney diseases</topic><topic>Kidneys</topic><topic>Liver cancer</topic><topic>Liver diseases</topic><topic>Lung cancer</topic><topic>Lung diseases</topic><topic>Male</topic><topic>Medicine and Health Sciences</topic><topic>Meta-analysis</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Mortality risk</topic><topic>Neoplasms - mortality</topic><topic>Obstructive lung disease</topic><topic>Pandemics</topic><topic>Patient outcomes</topic><topic>People and Places</topic><topic>Pneumonia, Viral - mortality</topic><topic>Prognosis</topic><topic>Renal failure</topic><topic>Renal Insufficiency, Chronic - mortality</topic><topic>Risk assessment</topic><topic>Survival</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ssentongo, Paddy</creatorcontrib><creatorcontrib>Ssentongo, Anna E</creatorcontrib><creatorcontrib>Heilbrunn, Emily S</creatorcontrib><creatorcontrib>Ba, Djibril M</creatorcontrib><creatorcontrib>Chinchilli, Vernon M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ssentongo, Paddy</au><au>Ssentongo, Anna E</au><au>Heilbrunn, Emily S</au><au>Ba, Djibril M</au><au>Chinchilli, Vernon M</au><au>Hirst, Jennifer A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2020-08-26</date><risdate>2020</risdate><volume>15</volume><issue>8</issue><spage>e0238215</spage><epage>e0238215</epage><pages>e0238215-e0238215</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Estimating the risk of pre-existing comorbidities on coronavirus disease 2019 (COVID-19) mortality may promote the importance of targeting populations at risk to improve survival. This systematic review and meta-analysis aimed to estimate the association of pre-existing comorbidities with COVID-19 mortality.
We searched MEDLINE, SCOPUS, OVID, and Cochrane Library databases, and medrxiv.org from December 1st, 2019, to July 9th, 2020. The outcome of interest was the risk of COVID-19 mortality in patients with and without pre-existing comorbidities. We analyzed 11 comorbidities: cardiovascular diseases, hypertension, diabetes, congestive heart failure, cerebrovascular disease, chronic kidney disease, chronic liver disease, cancer, chronic obstructive pulmonary disease, asthma, and HIV/AIDS. Two reviewers independently extracted data and assessed the risk of bias. All analyses were performed using random-effects models and heterogeneity was quantified.
Eleven pre-existing comorbidities from 25 studies were included in the meta-analysis (n = 65, 484 patients with COVID-19; mean age; 61 years; 57% male). Overall, the between-study heterogeneity was medium, and studies had low publication bias and high quality. Cardiovascular disease (risk ratio (RR) 2.25, 95% CI = 1.60-3.17, number of studies (n) = 14), hypertension (1.82 [1.43 to 2.32], n = 13), diabetes (1.48 [1.02 to 2.15], n = 16), congestive heart failure (2.03 [1.28 to 3.21], n = 3), chronic kidney disease (3.25 [1.13 to 9.28)], n = 9) and cancer (1.47 [1.01 to 2.14), n = 10) were associated with a significantly greater risk of mortality from COVID-19.
Patients with COVID-19 with cardiovascular disease, hypertension, diabetes, congestive heart failure, chronic kidney disease and cancer have a greater risk of mortality compared to patients with COVID-19 without these comorbidities. Tailored infection prevention and treatment strategies targeting this high-risk population might improve survival.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>32845926</pmid><doi>10.1371/journal.pone.0238215</doi><tpages>e0238215</tpages><orcidid>https://orcid.org/0000-0003-1565-5731</orcidid><orcidid>https://orcid.org/0000-0001-9104-1323</orcidid><orcidid>https://orcid.org/0000-0002-9868-5495</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2020-08, Vol.15 (8), p.e0238215-e0238215 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2437389491 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Acquired immune deficiency syndrome Aged AIDS Asthma Bias Biology and Life Sciences Cancer Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - mortality Cerebrovascular diseases Chronic diseases Chronic obstructive pulmonary disease Comorbidity Complications and side effects Congestive heart failure Coronary artery disease Coronavirus Infections - mortality Coronaviruses COVID-19 Diabetes Diabetes mellitus Diabetes Mellitus - mortality Failure analysis Female Health risks Heterogeneity HIV Human immunodeficiency virus Humans Hypertension Kidney diseases Kidneys Liver cancer Liver diseases Lung cancer Lung diseases Male Medicine and Health Sciences Meta-analysis Middle Aged Mortality Mortality risk Neoplasms - mortality Obstructive lung disease Pandemics Patient outcomes People and Places Pneumonia, Viral - mortality Prognosis Renal failure Renal Insufficiency, Chronic - mortality Risk assessment Survival Viral diseases |
| title | Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T07%3A27%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20cardiovascular%20disease%20and%2010%20other%20pre-existing%20comorbidities%20with%20COVID-19%20mortality:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=PloS%20one&rft.au=Ssentongo,%20Paddy&rft.date=2020-08-26&rft.volume=15&rft.issue=8&rft.spage=e0238215&rft.epage=e0238215&rft.pages=e0238215-e0238215&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0238215&rft_dat=%3Cgale_plos_%3EA633597924%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2437389491&rft_id=info:pmid/32845926&rft_galeid=A633597924&rft_doaj_id=oai_doaj_org_article_e7bb499c205145098753e03c77e55c4a&rfr_iscdi=true |